CLINICAL_TRIALS
trial_result
· 2023-01-09
Clinical Trial Update: A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash [Phase 2]
Summary
Phase 2 study of Imsidolimab (ANB019) for acneiform eruptions has been terminated, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vanda Pharmaceuticals | Conditions: Acneiform Eruptions | Phase 2 | Status: TERMINATED | Results posted: 2023-01-09